46 results about "Optic nerve injury" patented technology

The present invention relates to compositions of microspheres suitable for application to ocular injuries and inflammation, and to methods of use of the compositions alone or in combination with other agents in the prevention and treatment of ocular injuries and inflammation. The compositions, which increase the rate of healing, can be used to treat injuries and inflammation, including but not limited to those caused by foreign bodies, infections, burns, lesions, lacerations, ischemia, injuries from blunt trauma, traumatic hyphema, sympathetic ophthalmia, injuries from radiant energy, cataracts, corneal erosions or optic nerve injuries, and in procedures such as post-trabeculectomy (filtering surgery), post pterygium surgery; post ocular adnexa trauma and surgery, post intraocular surgery, post vitrectomy, post retinal detachment or post retinotomylectomy.

A method of inhibiting excitotoxicity by indirectly activating α4β2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of α7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate α4β2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.

The present invention discloses achyranthes bidentata polypeptide, a production method and applications, and the achyranthes bidentata polypeptide is produced with the steps including polypeptide extraction, polypeptide separation, etc. The achyranthes bidentata polypeptide is used to the preparation of drugs and health products for treating peripheral nerve injuries, cerebrovascular accidents, ischemic brain injuries, cerebral traumas, optic nerve injuries, spinal cord injuries and central nervous system injuries, antiaging and preventing neurodegenerative diseases. Experiments prove that the extracted achyranthes bidentata polypeptide (protein) of the present invention has the effects of promoting the growth of nerves, preventing the fading of nerve cells and promoting the regeneration of injured nerves, the source of medicinal materials is single, the preparation method is advanced, the technique is reasonable, the ingredients of preparations are definite, safety is high, and pharmacological action is obvious.

The invention belongs to the technical field of genetic engineering and nerve injuries. Optic nerve injuries are a lot of eye diseases and eye traumas, the optic nerve atrophy and blindness of patients can be caused when optic nerve injuries are severe, and at present, the clinical practical curative effect is not satisfactory. The research of the invention finds that the Neurithin gene is related to optic nerve injury repair, so the invention provides a Neurithin gene-carrying lentivirus vector and a construction method thereof and also further provides the application of the Neurithin gene-carrying lentivirus vector in the preparation of medicines for treating and repairing optic nerve injuries.

The invention belongs to the technical field of gene engineering and nerve injuries. Optic nerve injuries are common eye diseases and external injuries, and cause the optic nerve atrophia and blindness of patients when the optic nerve injuries are severe, and at present, the clinic actual curative effect is unsatisfactory. The invention provides a type-II adeno-associated virus carrying neuritin genes and a building method thereof, the invention also further provides the application of the type-II adeno-associated virus carrying neuritin genes in preparing medicaments for restoring optic nerve injuries.

The invention relates to the field of medical technology, and relates to the effective monomer component of lycopodium alkaloids isolated from Chinese folk herbal medicine Huperzia Serrata - huperzine A ((-)-huperzineA) in the preparation of treatment of glaucoma and / or Or use in medicine for ischemia-induced optic nerve damage. The structural formula of the compound huperzine A involved in the present invention is as follows. Experiments have confirmed that huperzine A has significant miotic effect and intraocular pressure-lowering effect on glaucoma animal models, and has obvious protective effects on retinopathy and apoptosis inflammatory protein expression in animals induced by ischemia or high intraocular pressure. Developed as a new drug for the treatment of glaucoma and / or ischemia-induced optic nerve damage. Huperzine A (-)-Huperzine A.

The present invention discloses uses of 7,8-dihydroxyflavone in preparation of drugs for treatment and / or prevention of optic nerve injury. The present invention further discloses a drug having the optic nerve protection effect, and is the preparation prepared by adopting 7,8-dihydroxyflavone as an active ingredient and adding a pharmaceutically-acceptable excipient or an auxiliary component. According to the present invention, the 7,8-dihydroxyflavone provides good protection effects on excitative optic nerve injury and optic nerve mechanical injury, can be used for repairing retinal ganglion cells, and is the new selection for clinical optic nerve injury treatment.

The invention relates to a method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury including the step of administering an effective amount of a peptide comprising the sequence: GlyArgArgAlaAlaProGlyArgAibGlyGly (SEQ ID NO:1) or the sequence GlyArgArgAlaAlaProGlyArgAibGlyGly-HN2 (SEQ ID NO:2) to a subject in need thereof.

The present invention relates to compositions of microspheres suitable for application to ocular injuries and inflammation, and to methods of use of the compositions alone or in combination with other agents in the prevention and treatment of ocular injuries and inflammation. The compositions, which increase the rate of healing, can be used to treat injuries and inflammation, including but not limited to those caused by foreign bodies, infections, burns, lesions, lacerations, ischemia, injuries from blunt trauma, traumatic hyphema, sympathetic ophthalmia, injuries from radiant energy, cataracts, corneal erosions or optic nerve injuries, and in procedures such as post-trabeculectomy (filtering surgery), post pterygium surgery; post ocular adnexa trauma and surgery, post intraocular surgery, post vitrectomy, post retinal detachment or post retinotomylectomy.

The invention relates to the technical field of gene engineering, and in particular to nucleic acid for encoding BDNF and application of the nucleic acid. According to the invention, a BDNF fragment which is efficiently expressed in vivo is obtained through codon optimization, so that an AAV vector for efficiently expressing BDNF, an adeno-associated virus and a medicine for treating eye diseasesare constructed. Experiments show that the AAV virus carrying the BDNF gene can directly infect retinal ganglion cells and continuously express BDNF protein for protecting and promoting optic nerve regeneration in target cells, so that retinal nerve cells after optic nerve injury are protected.

The invention discloses a Xuesaitong pharmaceutical composition and a preparation method, a preparation and application thereof. The Xuesaitong pharmaceutical composition is prepared from the following components in percentage by mass: 0.001 to 99.996% of ginsenoside Rb2, 0.001 to 99.996% of ginsenoside Rb1, 0.001 to 99.996% of ginsenoside Rg1, 0.001 to 99.996% of ginsenoside Rc, and 0.001 to 99.996% of notoginsenoside R1. The Xuesaitong pharmaceutical composition and the preparation have the advantages that the obvious treatment effect on ischemic cardiovascular and cerebrovascular diseases of myocardial infarction, cerebral apoplexy, cerebral infarction, brain hemiplegia and the like, and the retinopathy or optic nerve injury disease due to ischemic cardiovascular and cerebrovascular diseases, diabetes and the like is realized, and the application prospect is broad; compared with the prior art and the product, the treatment effect is better, the safety is higher, and the requirementof clinical medicine usage can be well met; the technology of the preparation method is simple, the conditions are mild, the operation is convenient, the quality is stable and controllable, and the preparation method is suitable for industrialized large-scale production.

An object of the present invention is to search for a novel medicinal use of a compound having a secretase inhibitory activity. Because the compound having a secretase inhibitory activity has a remarkable inhibitory effect on retinal neuronal cell death, it is useful as a therapeutic agent for a retinal disease typified by retinal vessel occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, retinitis pigmentosa and Leber's disease or an eye disease accompanied by an optic neuropathy such as glaucoma.

The invention relates to the technical field of genetic engineering, aims to solve the major clinical medical problem of how to effectively treat an injured optic nerve with low intrinsic retinal ganglion cell regeneration capability which is the key factor for recovery of the visual function, and provides a Pim-1 gene-containing recombinant adeno-associated virus 2 vector and a construction method for the same. The adeno-associated virus 2 vector is a DNA (deoxyribonucleic acid) sequence containing a Pim-1 gene shown as SEQ ID NO:1. The invention also provides the application of the Pim-1 gene-containing recombinant adeno-associated virus 2 vector to preparation of a medicament for treating and repairing the injured optic nerve. Novel powerful means and a theoretical foundation are provided for clinical treatment of optic nerve injuries, and the Pim-1 gene-containing recombinant adeno-associated virus 2 vector is significant for treatment of CNS (central nervous system) diseases and injuries.

The invention discloses an application of knocking down ARID1A in inhibition of retinal ganglion cell apoptosis after injury. The invention finds that the ARID1A gene knockout can inhibit the RGC apoptosis of optic nerve injury animals, and the survival rate of the RGC after the ARID1A gene knockout is obviously increased compared with that of the RGC without the ARID1A gene knockout, so that the ARID1A gene knockout substance can be used as a protective agent of retinal ganglion cells to treat optic nerve injury. The invention provides a new gene intervention target spot to effectively inhibit the apoptosis of the retinal ganglion cells after optic nerve injury, and provides a strategy for repairing optic nerve injury, searching a treatment method for optic nerve injury to relieve the pain of a patient and restore the neurological function.

The invention relates to vaccine eye drops used for treating and preventing glaucoma, which are characterized in that the eye drops comprise Nogo66 protein and chitosan, wherein the volume ratio of the Nogo66 protein to the chitosan is 1:1, the concentration of the Nogo66 protein is 0.1-1.5mg / ml, and the concentration of chitosan is 1-15mg / ml. The vaccine eye drops are used for optic nerve injury caused by the apoptosis or the traumatism of retina ganglionic cells caused by the glaucoma, can effectively improve the micro-environment of the injured neuron, induce the restoration and regeneration of the neuron and have the advantages of safe use, low price and convenient inoculation.

The present invention relates to methods to treat and / or prevent optic nerve damage in a subject by administering a composition comprising a crystallin agonist.

The invention discloses an optic nerve clamp for an optic nerve injury model, and belongs to the field of clamping devices. The clamp comprises two strip-shaped rigid clamping pieces which are completely symmetrical in structure, wherein each clamping piece comprises a root portion, a middle portion and a tip portion; the root portions of the two clamping pieces are welded together; the middle portions of the two clamping pieces are force application areas; force is applied to enable the clamp to conduct clamping; and the tip portions are in a separated state when the clamp is not stressed, and the tail ends of the tip portions are bent. The clamp is characterized in that three holes are correspondingly formed in each of the middle portions of the two clamping pieces in the deformation direction of the clamping pieces when the clamping pieces receive an applied force and conduct clamping; a screw rod and a screw cap are arranged in each hole; when the screw rods and the screw caps arein threaded connection, both the heads of the screw rods and the screw caps are located on the outer sides of the two clamping pieces; and the clamp clamps an optic nerve through screwing-in of the screw caps on the screw rods. The clamp has the advantages of stable clamping, high reliability, capability of conducting quantitative injury on optic nerves and convenience in operation by a user.

The invention provides a novel application of magnolol. The magnolol disclosed by the invention can be used for reducing retinal ganglion cell loss and retinal damage caused by intraocular hypertension; the visual function reduction caused by intraocular hypertension is improved; the generation of inflammatory factors in retinal tissues caused by intraocular hypertension is inhibited; the activation of microglial cells and astrocytes in the retina caused by intraocular hypertension can be reduced, phenotypic polarization of the microglial cells to M1 can be reduced, and phenotypic polarization of the microglial cells to M2 can be promoted; the decrease of blood retina barrier related protein in the retina tissue caused by intraocular hypertension is relieved; and the increase of the proportion of Th1, Th2 and Th17 cells in ocular reflux lymph nodes caused by intraocular hypertension is reduced. Magnolol can be used for preventing, treating or relieving optic nerve injury caused by glaucoma diseases.

The invention discloses a photobiological regulation therapeutic instrument for treating open-angle glaucoma and a using method. According to the photobiological regulation therapeutic instrument, near-infrared light with a wavelength of 600-800 nm relative to light-emitting viewpoints of a left eye sight glass and a right eye sight glass is set to activate photoreceptors in eye cells of a glaucoma patient, promote light energy to be converted into metabolic energy, reduce intraocular pressure of a glaucoma patient, and provide greater possibility for vision recovery of the patient. On one hand, by irradiating the eyeball-ciliary body, aqueous humor generation is reduced, aqueous humor backflow is promoted, intraocular pressure is reduced, on the other hand, glaucoma optic nerve damage can be reduced and injured optic nerve repair can be promoted through low-dose red light irradiation, and in addition, neurons of optic nerves need high-energy mitochondria ATP to meet tissue requirements, and are very sensitive to glucose consumption or energy deficiency, oxidative stress, and mitochondrial dysfunction. Near-infrared light can promote mitochondrial injury repair and improve mitochondrial functions, and has important application value in optic nerve injury treatment.

The invention discloses an external medicine for nerve injury caused by wrist traumas, which aims to solve the problem of treatment after wrist nerve injury operation. The invention is characterized by comprising the following active pharmaceutical ingredients in parts by weight: Solanum lyratum, rhizoma pleionis, ipomoea pes-caprae, Herb of Paniculate Spotflower, securinega suffruticosa, mulberry seed, himalayan teasel root, dried orange peel, Cassia alata, Viburnum foetidrm Wall., Amblystegium serpens and Cladostachys amaranthoides. The clinical experiment proves that the invention has the characteristics of favorable curative effect and higher safety after wrist nerve injury operation, and is worthy of clinical application and popularization.

The present invention relates to the treatment of non-cranial nervous system injury, such as spinal cord injury and / or optic nerve injury, with an SCO-Spondin-derived peptide administered to a patient by systemic route. The present invention relates to a peptide having the amino acid sequence X1-W-S-A1-W-S-A2-C-S-A3-A4-C-G-X2 wherein A1, A2, A3 and A4 consist of an amino acid sequence consisting of 1 to 5 amino acids and X1 and X2 consist of an amino acid sequence consisting of 1 to 6 amino acids; or X1 and X2 are absent; the N-terminal amino acid can be acetylated, the C-terminal amino acid can be amidated, or the N-terminal amino acid can be acetylated and the C-terminal amino acid can be amidated. The use of such peptides for remyelination is also described.

The present invention relates to the application in nerve injury and drug combination with the drug for treating nerve injury, administered through the oral route and administered by intraperitoneal injection, enema, gavage, intravenous injection, subcutaneous injection, intramuscular injection and suppository It can effectively prevent and treat various nerve injuries, mainly including optic nerve, spinal nerve injury, oculomotor nerve injury and other cranial nerve injuries.

The invention belongs to the technical field of biomedical experiments, and relates to a construction method of an animal model, in particular to a method and a device for constructing an optic nerve injury model. An optic nerve injury model is constructed by using a specific device, and the method comprises the following steps: sleeving optic nerves with a pressurizing ring of the device behind a ball; the sutures located in the threading holes are aligned and knotted, and the circular ring is closed; a piston of the air injection cylinder is pushed to inject air into the pressurizing ring, and after air injection is completed, the piston is fixed; and after pressurization is completed, the piston is retracted, the suture is released after air in the pressurization ring is sucked out, and the pressurization ring is taken to construct the optic nerve injury model. According to the model, the injury degrees of the retinal ganglion cells at different parts of the retina approach to be consistent, and the injury to the arteriovenous blood vessel wall of the retina is reduced. The method disclosed by the invention is simple and feasible in process, and is easy to popularize in related researches of optic nerve injury diseases according to verification.

The invention discloses an application of minocycline in protection of retinal ganglion cells. The invention discloses the application of minocycline in preparation of products for protecting the retinal ganglion cells. Minocycline is proved to play a nerve protection role to a certain extent by an autophagy and NF-kappa B regulating way at early stage after optic nerve injury, and have high application prospects in clinical treatment after optic nerve injury.

The invention provides an application of gingko diterpene lactone in preparation of optic nerve injury drugs, the gingko diterpene lactone is selected from a composition containing ginkgolide A, ginkgolide B and ginkgolide K, and the ratio of ginkgolide A to ginkgolide B to ginkgolide K is (20-40): (50-75): (0.2-5.0). The gingko diterpene lactone provided by the invention has the effects of expanding blood vessels, increasing blood flow and repairing and protecting optic nerves, can be applied to treatment of optic nerve injury, posterior globular neuritis and retinitis, and can also be applied to relief of asthenopia. The gingko diterpene lactone is prepared into an ophthalmic preparation, so that the problem of low solubility of the gingko diterpene lactone is solved, and the contact time of a medicine and cornea is prolonged by increasing the viscosity, so that the bioavailability can be improved.